Bisphosphonates (BPs) are the most widely used and effective treatment for osteoporosis and Pagets disease of the bone. To date, a number of BPs-namely alendronate, risedronate, and minodronate-have been launched to market. Nitrogen-BPs (N-BPs) act by inhibiting the enzyme farnesyl pyrophosphate synthase (FPPS), and several crystal structures of complexes between FPPS and N-BPs have been identified. Understanding the physical basis of the binding between proteins and small molecules is an important goal in both medicinal chemistry and structural biology. Here, we conducted density functional theory calculations for BPs and their surrounding residues and were able to successfully reproduce experimental results qualitatively. In addition, we found that both the side chain and backbone of Phe 99 are important for binding between minodronate and FPPS, suggesting that the strong activity of minodronate comes from its interaction with Phe 99, which alendronate and risedronate lack.
Introduction
Bisphosphonates (BPs) are the most widely used and effective treatment for osteoporosis and Pagets disease of the bone [1] , and a number of BPs have been launched to market. All BPs contain a phosphate-carbon-phosphate (P-C-P) backbone structure and can be classfied into two groups: non-nitrogen-containing BPs (non-N-BPs) and nitrogencontaining BPs (N-BPs), which are further divided into two additional groups (alkyl-amino BPs and heterocyclic NBPs) [2] ,. N-BPs act by inhibiting farnesyl pyrophosphate synthase (FPPS), which is a key enzyme in the mevalonate pathway ( Fig. 1) [3] . Farnesyl pyrophosphate synthetase (FPS; EC 2.5.1.10) produces the 15-carbon farnesyl pyrophosphate which is utilized in the synthesis of sterols, dolichols, carotenoids, coenzyme Q, heme a, and farnesylated proteins. Several crystal structures of human FPPS complexed with N-BPs have been published. In a previous study, we conducted an interaction energy analysis using the fragment molecular orbital (FMO) method [4] . Our findings indicated that the following interactions may be important in the potency of N-BPs: hydrogen bonding with Thr 201 and/or Lys 200, where a bifurcated bond is more potent than a single bond; CH-O hydrogen bonding with the backbone carbonyl oxygen atom of Phe 99; andinteraction with the sidechain of Phe 99. Truhlars group recently developed the global hybrid meta functionals M05-2X [5] and M06-2X [6] and demonstrated that these methods can be effectively applied to many problematic systems [7, 8] . Here, we conducted quatum mechanical calculations for several BPs (minodronate, risedronate, alendronate) and their surrounding residues using the M06-2X method.
Methods
To construct our model, three-dimensional coordinates of the FPPS/BP complex were obtained from Protein Data Bank (2F92 for alendronate [9] , 1YV5 for risedronate [10] , and 3B7L for minodronate [11] ). Both side chains of the BPs and surrounding amino acid residues (within 4.5Åof the side chain of minodronate) were cut from the crystal structures, including the BP, Phe 99, Leu 100, Asp 103, Thr 167, Gln 171, Lys 200, Thr 201, Tyr 204, and Gln 240 ( Fig. 1 ). For Lys 200 and Asp 103, uncharged protonation was used. Addition and energy minimization of hydrogen atoms was conducted using MOE 2008.1001 (Chemical Computing Group, Inc., Quebec, Canada), a model classified as wild. To examine the effect of Phe 99 on the interaction between FPPS and BP, Phe 99 was removed from the wild system, in a model known as delF99. To examine the side chain of Phe 99, Phe 99 was substituted for alanine, and energy minimization of the side chain was conducted, in a model known as F99A. The Gaussian 09 program was used for the ab initio molecular orbital calculations. Energy was calculated using M06-2X/6-31G* [6] . Each interaction enery value was calculated using the following equation:
where G bind is the binding energy, E(BP+AA,v) the energy of BP and amino acids complex it in vacuo, E(BP,w) the energy of BP in water, and E(AA,v) the energy of amino acids in vacuo.
Fig. 1. Side chain of minodronate and surrounding residues

Results and Discussion
Binding energy values calculated using M06-2X/6-31G* are summarized in Table 1 . The binding energy of minodronate was the smallest among the three bisphosphates tested (-3.9 kcal/mol), while that of alendronate was the largest (7.9 kcal/mol). These results are consistent with previously obtained experimental data [12] . For minodronate, the binding energy of F99A was larger than that of the wild system by 2.3 kcal/mol, indicating that the side chain of F99 has a significant interaction with minodronate. Further, the binding energy of dF99 was larger than that of F99A by 5.3 kcal/mol, indicating that the backbone of F99 also has a significant interaction with minodronate, due to the CH-O hydrogen bond between the backbone of F99 and minodronate. For risedronate, the binding energy of dF99 was larger than that of the wild system by 3.1 kcal/mol, indicating that F99 has a moderate interaction with risedronate. Further, the binding energy of dF99 was almost the as same as that of F99A, indicating that the sidechain of F99 has little interaction with risedronate. For alendronate, the binding energy of dF99 is almost the as same as that of the wild system, indicating that F99 does not have a significant interaction with alendronate. In contrast, with HF/6-31G*, the respective binding energies of minodronate, risedronate, and alendronate were 26.5, 11.8, and 16.1 kcal/mol, showing that the binding energy of minodronate is quite larger than that of alendronate. This underestimation of the binding energy of minodronate may be due to the fact that HF calculations cannot accurately estimate CH-O hydrogen bonding and π-π interactions, two major driving forces of binding between BP and FPPS as determined in our previous study [4] . Here, we described preliminary findings regarding interaction between bisphosphates and their surrounding residues. Our calculations qualitatively reproduced previous experimental findings and indicated that both the side chain and backbone of Phe 99 are important for binding between minodronate and FPPS. The characteristics of three BPs (minodronate, risedronate, and alendronate) are summarized in Table 2 . All three BPs have a hydrogen bond with Thr 201, and both minodronate and risedronate have a hydrogen bond with Lys 200. The CH-O hydrogen bond with Phe 99, however, is a unique feature of minodronate, and thus the strong binding of minodronate to FPPS is determined to be due to these three hydrogen bonds, termed a triple hydrogen bond. Minodronate is a third generation BP originally developed at Astellas Pharma which was approved and launched in 2009 in Japan as an oral treatment for osteoprosis. Minodronate was synthesized by a team lead by one of the authors (M. Takeuchi) and has been shown to have 100-to 1000-fold stronger bone resorption activity than pamidronate [13] . Although minodronate shows the strongest activity among BPs, the reason for its strong activity remains unclear. As described in the Introduction, our previous calculations using the FMO method indicated that hydrogen bonding with Thr 201 and/or Lys 200, CH-O hydrogen bonding with the backbone of Phe 99, and π-π interactions with the sidechain of Phe 99 are all important for binding between minodronate and FPPS [4] . The results obtained in the present study support the above hypothesis.
Further work is underway to improve the calculation.
• The coordinates for quantum mechanical calculation will be optimized using M06-2X. 
Fig. 2. Comparision of three BPs
• Larger basis sets (such as 6-311+G(d,p)) will be used for quantum mechanical calculations.
• The basis set surperposition error (BSSE) will be estimated using the counterpoise method [14, 15] .
• The effect of protonation states will be considered.
Conclusion
Results of M06/02X calculations for several BPs and their surrounding residues Showed that Phe 99 in FPPS is important for binding between minodronate and FPPS. The M06/02X calculation is a promising tool for providing deeper insight into interaction between drugs and receptors.
